Efficacy and Safety Trial of the ALK HDM Tablet in House Dust Mite Allergic Subjects
Phase 2
Completed
- Conditions
- Asthma
- Registration Number
- NCT00389363
- Lead Sponsor
- ALK-Abelló A/S
- Brief Summary
The purpose of the trial is to determine if treatment of asthma patients allergic to house dust mites with the ALK HDM tablet can reduce the need of inhaled corticosteroids (ICS).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 800
Inclusion Criteria
- A history of house dust mite induced asthma
- Use of inhaled corticosteroids (ICS)
- Positive skin prick test to house dust mites
- Positive specific IgE to house dust mites
Exclusion Criteria
- FEV1 lower than 70%
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Use of inhaled corticosteroid (ICS).
- Secondary Outcome Measures
Name Time Method Use of rescue medication and symptoms. Quality of Life.
Trial Locations
- Locations (1)
Rigshospitalet
🇩🇰Copenhagen, Denmark